RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nichi-Iko Pharmaceutical Co Stock

Nichi-Iko Pharmaceutical Co Revenue 2025

Nichi-Iko Pharmaceutical Co Revenue

217.76 B JPY

Ticker

4541.T

ISIN

JP3687200000

WKN

A0DQVE

In 2025, Nichi-Iko Pharmaceutical Co's sales reached 217.76 B JPY, a 7.91% difference from the 201.8 B JPY sales recorded in the previous year.

The Nichi-Iko Pharmaceutical Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2027e225.131,76
2026e222.351,78
2025e217.761,82
2024e201.81,97
2023e192.912,06
2022179.062,21
2021188.2211,29
2020190.0819,63
2019166.5919,90
2018164.7224,77
2017149.2625,20
2016143.5137,29
2015127.0237,07
2014103.6238,29
201393.9339,04
20122737,25
201177.7440,28
201064.3542,58
200954.8144,46
200842.8446,86
200732.3348,26
200629.2547,08
200524.346,91
200418.348,37
200317.6549,15

Nichi-Iko Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nichi-Iko Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nichi-Iko Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nichi-Iko Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nichi-Iko Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nichi-Iko Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nichi-Iko Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nichi-Iko Pharmaceutical Co’s growth potential.

Nichi-Iko Pharmaceutical Co Revenue, EBIT and net profit per share

DateNichi-Iko Pharmaceutical Co RevenueNichi-Iko Pharmaceutical Co EBITNichi-Iko Pharmaceutical Co Net Income
2027e225.13 B undefined0 undefined-156.5 B undefined
2026e222.35 B undefined0 undefined-96.34 B undefined
2025e217.76 B undefined0 undefined-59.9 B undefined
2024e201.8 B undefined0 undefined-109.65 B undefined
2023e192.91 B undefined0 undefined-535.14 B undefined
2022179.06 B undefined-28.29 B undefined-104.98 B undefined
2021188.22 B undefined1.86 B undefined-4.18 B undefined
2020190.08 B undefined6.86 B undefined5.13 B undefined
2019166.59 B undefined7.41 B undefined6.86 B undefined
2018164.72 B undefined13.27 B undefined8.07 B undefined
2017149.26 B undefined6.8 B undefined4.8 B undefined
2016143.51 B undefined12.67 B undefined11.03 B undefined
2015127.02 B undefined9.62 B undefined6.59 B undefined
2014103.62 B undefined7.38 B undefined4.59 B undefined
201393.93 B undefined8.23 B undefined5.13 B undefined
201227 B undefined2.15 B undefined1.33 B undefined
201177.74 B undefined7.51 B undefined3.91 B undefined
201064.35 B undefined7.22 B undefined3.87 B undefined
200954.81 B undefined6.09 B undefined3.76 B undefined
200842.84 B undefined5.41 B undefined3.44 B undefined
200732.33 B undefined4.34 B undefined2.62 B undefined
200629.25 B undefined3.85 B undefined2.41 B undefined
200524.3 B undefined2.43 B undefined1.24 B undefined
200418.3 B undefined2.56 B undefined143 M undefined
200317.65 B undefined2.7 B undefined2.36 B undefined

Nichi-Iko Pharmaceutical Co stock margins

The Nichi-Iko Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nichi-Iko Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nichi-Iko Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nichi-Iko Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Nichi-Iko Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nichi-Iko Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nichi-Iko Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nichi-Iko Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nichi-Iko Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nichi-Iko Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nichi-Iko Pharmaceutical Co Margin History

Nichi-Iko Pharmaceutical Co Gross marginNichi-Iko Pharmaceutical Co Profit marginNichi-Iko Pharmaceutical Co EBIT marginNichi-Iko Pharmaceutical Co Profit margin
2027e2.21 %0 %-69.52 %
2026e2.21 %0 %-43.33 %
2025e2.21 %0 %-27.51 %
2024e2.21 %0 %-54.34 %
2023e2.21 %0 %-277.4 %
20222.21 %-15.8 %-58.63 %
202111.29 %0.99 %-2.22 %
202019.63 %3.61 %2.7 %
201919.9 %4.45 %4.12 %
201824.77 %8.06 %4.9 %
201725.2 %4.56 %3.21 %
201637.29 %8.83 %7.69 %
201537.07 %7.57 %5.19 %
201438.29 %7.12 %4.43 %
201339.04 %8.77 %5.46 %
201237.25 %7.95 %4.93 %
201140.28 %9.66 %5.03 %
201042.58 %11.22 %6.01 %
200944.46 %11.12 %6.87 %
200846.86 %12.62 %8.03 %
200748.26 %13.42 %8.1 %
200647.08 %13.17 %8.22 %
200546.91 %10 %5.11 %
200448.37 %14.01 %0.78 %
200349.15 %15.31 %13.37 %

Nichi-Iko Pharmaceutical Co Aktienanalyse

What does Nichi-Iko Pharmaceutical Co do?

Nichi-Iko Pharmaceutical Co Ltd is a Japanese company founded in 1965 by Shin-ichi Oka. The company is now one of the largest generic drug manufacturers in Japan and has also made a name for itself in the international market in recent years. Nichi-Iko currently employs about 4800 people and is headquartered in Toyama, Japan. The business model of Nichi-Iko is focused on producing high-quality and cost-effective generic drugs for the global market. The company has an extensive research and development department that continuously develops and improves new products. The goal is to offer a wide range of medicines to meet the needs of patients in different countries. Nichi-Iko has various divisions that the company focuses on. One of the most important divisions is oncology products. Nichi-Iko has a wide range of products for cancer treatment on the market. The company has also expanded into other areas such as infectious diseases, cardiology, neurology, and dermatology. The product range includes tablets, capsules, injection solutions, eye drops, and inhalation products. The company also has an extensive distribution infrastructure that focuses on strengthening its global presence. Nichi-Iko has branches in Japan, the United States, Europe, and Asia. The presence in the global market has helped the company distribute its products in more than 50 countries. Nichi-Iko places a high value on quality control. The company has quality control facilities such as the central laboratory and research and development department. The company takes responsibility for the quality of its products and enables doctors and pharmacists to prescribe safe and effective medicines to their patients. Nichi-Iko also strives for a more sustainable future. The company is committed to promoting environmentally friendly business practices. Nichi-Iko is committed to reducing its energy and water consumption, as well as reducing its waste products. The company has also launched an initiative to promote medication recycling in order to expand the possibilities of using medical waste. In summary, Nichi-Iko Pharmaceutical Co Ltd is a leading generic drug manufacturer focused on producing high-quality and cost-effective medicines. The company has expanded into various areas and operates in the global market. Nichi-Iko places great importance on quality control and is committed to being more environmentally friendly. Nichi-Iko Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Nichi-Iko Pharmaceutical Co's Sales Figures

The sales figures of Nichi-Iko Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Nichi-Iko Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Nichi-Iko Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Nichi-Iko Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Nichi-Iko Pharmaceutical Co stock

How much revenue did Nichi-Iko Pharmaceutical Co generate this year?

Nichi-Iko Pharmaceutical Co has achieved a revenue of 217.76 B JPY this year.

How much was the turnover of the company Nichi-Iko Pharmaceutical Co compared to the previous year?

The revenue of Nichi-Iko Pharmaceutical Co has increased by 7.91% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Nichi-Iko Pharmaceutical Co?

The revenue of Nichi-Iko Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Nichi-Iko Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Nichi-Iko Pharmaceutical Co so important for investors?

The revenue of Nichi-Iko Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Nichi-Iko Pharmaceutical Co pay?

Over the past 12 months, Nichi-Iko Pharmaceutical Co paid a dividend of 20 JPY . This corresponds to a dividend yield of about 57.14 %. For the coming 12 months, Nichi-Iko Pharmaceutical Co is expected to pay a dividend of -42.49 JPY.

What is the dividend yield of Nichi-Iko Pharmaceutical Co?

The current dividend yield of Nichi-Iko Pharmaceutical Co is 57.14 %.

When does Nichi-Iko Pharmaceutical Co pay dividends?

Nichi-Iko Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of April, October, April, October.

How secure is the dividend of Nichi-Iko Pharmaceutical Co?

Nichi-Iko Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Nichi-Iko Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to -42.49 JPY are expected. This corresponds to a dividend yield of -121.39 %.

In which sector is Nichi-Iko Pharmaceutical Co located?

Nichi-Iko Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nichi-Iko Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nichi-Iko Pharmaceutical Co from 12/1/2021 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 9/29/2021.

When did Nichi-Iko Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2021.

What was the dividend of Nichi-Iko Pharmaceutical Co in the year 2024?

In the year 2024, Nichi-Iko Pharmaceutical Co distributed 0 JPY as dividends.

In which currency does Nichi-Iko Pharmaceutical Co pay out the dividend?

The dividends of Nichi-Iko Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nichi-Iko Pharmaceutical Co

Our stock analysis for Nichi-Iko Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nichi-Iko Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.